

Kihara discloses phenyl derivatives of the indicated imidazoles, and a single unsubstituted thiophene derivative thereof. The above referenced proviso thus specifically excludes from all the pending claims compounds of the structure disclosed in Kihara, since both a phenyl group and a thiophene group are fully unsaturated 6 and 5 member rings structures, respectively.

*Rejection of Claims 1-108 Pursuant to 35 USC §103(a)*

The Examiner has again rejected claims 1-108 as allegedly obvious over Toyko (WO94-07866 or Orion (WO97-12874) or Zhang et al. Applicants respectfully traverse this rejection for the following reasons.

As stated in the last communication, the present invention is directed to compounds having a particular structure and which are selective agonists of the alpha 2<sub>B</sub> and/or 2<sub>B</sub> and 2<sub>C</sub> adrenergic receptor subtypes. Thus, the claimed compounds are defined by structural and functional limitations, and the patentability of each of the rejected claims must be considered in light of all its limitations.

The Examiner has incorrectly stated that “[a]pplicants must agree with the rejection to Zhang et al. since no arguments were presented as to why the patented subject matter is patentable over this reference.” In fact, the argument on pages 7 and 8 of that Reply are addressed generally to the rejection in view of all (and each of) the references.

In repeating the rejection over the above-cited references, the Examiner has not addressed the points made on pages 7-10 of the Applicants’ Reply, which is hereby incorporated by reference as part of this Reply. The Examiner has stated generally that the Applicants have not provided any showing of inobvious properties of the claimed molecules. Applicants respectfully submit this is not the case, and moreover, that the Examiner’s Action fails to address each claim as a whole, including its functional limitations. The Examiner states that “[t]o be a viable reference the reference has to disclose structurally similar compounds which would render the claimed compounds structurally obvious and have a viable utility – this utility does not have to be the same [sic] utility applicants disclose for the claimed compounds.” While Applicants have no opinion whether this rule might be true for a claim containing only structural limitations, it is decidedly untrue in the present case, in which each and every claim contains functional limitations.

As indicated in the prior Reply, the claimed molecules must be selective or specific for agonist activity at the alpha 2B and or the alpha 2C over the alpha 2A receptor. Despite the Examiner's assertions, Table 1, beginning on page 87, provides experimental evidence of the unexpected properties of the claimed compounds.

Finally, the Examiner has failed to provide any evidence, as he must in order to establish a *prima facie* case of obviousness, that the disclosed selective agonist activity was suggested by the prior art or that there existed motivation in the prior art to find the claimed set of compounds, limited as they are by this function.

### CONCLUSION

For the above reasons Applicants believe the claims are now in condition for allowance, and respectfully request that the Examiner issue a Notice to that effect. No fee is thought to be required in connection with this communication. However, if Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Date: 5/2/02

Respectfully Submitted,




Carlos A. Fisher  
Reg. No. 36,510  
ALLERGAN, INC.  
T2-7H  
2525 Dupont Drive  
Irvine, CA 92612  
Tel: 714-246-4920  
Fax: 714-246-4249


MARKED-UP VERSION OF THE AMENDMENTS

*In the Claims:*

1.3 (Twice Amended) A compound having a structure selected from the group consisting of:



and



in which each x is independently 1 or 2;

each  $R_1$  is independently selected from the group consisting of H; halogen;  $C_{1-4}$  alkyl;  $C_{1-4}$  alkenyl;  $C_{1-4}$  alkynyl;  $--COR_4$  where  $R_4$  is H,  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy;  $C_{3-6}$  cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or  $-(CH_2)_n-X-(CH_2)_m-(R_5)_o$  where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and  $R_5$  is methyl or  $H_{1-2}$ ;

each  $R_2$  and each  $R_3$  are independently selected from the group consisting of H; halogen;  $C_{1-4}$  alkyl;  $C_{1-4}$  alkenyl;  $C_{1-4}$  alkynyl;  $--COR_4$  where  $R_4$  is H;  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy;  $C_{3-6}$  cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or  $-(CH_2)_n-X-(CH_2)_m-(R_5)_o$  where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and  $R_5$  is methyl or  $H_{1-2}$ ; or an  $R_2$  and an  $R_3$  together consist of ~~comprise~~ a saturated, partly saturated, or unsaturated ring structure having the formula  $-(C(R_6)_{p_1})_{q_1}-X_5-(C(R_6)_{p_2})_{r_2}-X_6-(C(R_6)_{p_3})_{u_3}$  where each  $R_6$  is independently

selected from the group consisting of H; halogen; C<sub>1-4</sub> alkyl; C<sub>1-4</sub> alkenyl; C<sub>1-4</sub> alkynyl; --COR<sub>4</sub> where R<sub>4</sub> is H, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy; C<sub>3-6</sub> cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl and oxo where each p is independently 1 or 2, q is 0-5, r is 0-5, u is 0-5; each X is independently O, S, or N and s is 0 or 1; provided that q + r + u + s + t is less than 6; Y is selected from the group consisting of O; S; N; --(C(R<sub>7</sub>)<sub>z</sub>)<sub>s</sub>—where each R<sub>7</sub> is independently as previously defined for R<sub>1</sub>, each z is independently 1-2, and s is 1-3; --CH=; --CH=CH--; or Y<sub>1</sub>CH<sub>2</sub>—where Y<sub>1</sub> is O, N, or S; and the dotted lines are optional double bonds, with the proviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsaturated, and that if Y is O, N or S, the ring including Y contains at least one said double bond, said compound further having selective agonist activity at the α<sub>2</sub>B or α<sub>2</sub>B/α<sub>2</sub>C adrenergic receptor subtype(s) over the α<sub>2</sub>A adrenergic receptor subtype, and/or all pharmacologically acceptable salts, esters, stereoisomers or racemic mixtures thereof.

2.4. (Twice Amended) The compound of claim 1 in which the ring including Y has either a single double bond or no double bond, except that when an R<sub>2</sub> and an R<sub>3</sub> together consist of ~~comprise~~ a saturated, unsaturated or partly saturated ring structure said Y-including ring optionally shares an additional double bond with said condensed ring, provided Y is not S, O, or N.

9.11. (Twice Amended) The compound of claim 2, in which each R<sub>2</sub> and each R<sub>3</sub> are independently selected from the group consisting of: H; C<sub>1-4</sub> alkyl; C<sub>1-4</sub> alkenyl; C<sub>1-4</sub> alkynyl; halide; trihalomethyl; cycloalkyl; (CH<sub>2</sub>)<sub>n</sub>-X-(CH<sub>2</sub>)<sub>m</sub>-(R<sub>5</sub>)<sub>o</sub>, where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R<sub>5</sub> is methyl or H<sub>1-2</sub>; or an R<sub>2</sub> and an R<sub>3</sub> together consist of ~~comprise~~ a saturated, partly saturated, or unsaturated ring structure having the formula --(C(R<sub>6</sub>)<sub>p</sub>)<sub>q</sub>-X<sub>s</sub>-(C(R<sub>6</sub>)<sub>p</sub>)<sub>r</sub>-X<sub>t</sub>-(C(R<sub>6</sub>)<sub>p</sub>)<sub>u</sub> where each R<sub>6</sub> is independently selected from the group consisting of H; halogen; C<sub>1-4</sub> alkyl; C<sub>1-4</sub> alkenyl; C<sub>1-4</sub> alkynyl; --COR<sub>4</sub> where R<sub>4</sub> is H, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy; C<sub>3-6</sub> cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; and oxo where each p is independently 1 or 2, q is 0-4, r is 0-4, u is 0-4; each X is independently O, S, or N, s is 0 or 1, and q + s + r + t + u = 3 or 4.

1012. (Twice Amended) The compound of claim 3, in which each  $R_2$  and each  $R_3$  are independently selected from the group consisting of: H;  $C_{1-4}$  alkyl;  $C_{1-4}$  alkenyl;  $C_{1-4}$  alkynyl; halide; trihalomethyl; cycloalkyl;  $(CH_2)_n-X-(CH_2)_m-(R_5)_o$ , where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and  $R_5$  is methyl or  $H_{1-2}$ ; or an  $R_2$  and an  $R_3$  together consist of ~~comprise~~ a saturated, partly saturated, or unsaturated ring structure having the formula  $-(C(R_6)_p)_q-X_s-(C(R_6)_p)_r-X_t-(C(R_6)_p)_u$  where each  $R_6$  is independently selected from the group consisting of H; halogen;  $C_{1-4}$  alkyl;  $C_{1-4}$  alkenyl;  $C_{1-4}$  alkynyl;  $--COR_4$  where  $R_4$  is H,  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy;  $C_{3-6}$  cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; and oxo where each p is independently 1 or 2, q is 0-4, r is 0-4, u is 0-4; each X is independently O, S, or N, s is 0 or 1, and  $q + s + r + t + u = 3$  or 4.

71. (Twice Amended) The compound of claim 53 in which an  $R_2$  and an  $R_3$  together consist of ~~comprise~~ a saturated, partly saturated, or unsaturated ring structure having the formula  $-(C(R_6)_p)_q-X_s-(C(R_6)_p)_r-X_t-(C(R_6)_p)_u$  where each  $R_6$  is independently selected from the group consisting of H; halogen;  $C_{1-4}$  alkyl;  $C_{1-4}$  alkenyl;  $C_{1-4}$  alkynyl;  $--COR_4$  where  $R_4$  is H,  $C_{1-4}$  alkyl or  $C_{1-4}$  alkoxy;  $C_{3-6}$  cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; and oxo where each p is independently 1 or 2, q is 0-4, r is 0-4, u is 0-4; each X is independently O, S, or N, s is 0 or 1, and  $q + s + r + t + u = 3$  or 4.